Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.31 |
| ▸ | TNKS | O95271 | 2/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371095 | 0.90 | GRM2 (0.35) | ESR2DGAT1CYP2C9OPRL1SOAT1 | |
| SCHEMBL8767259 | 0.82 | ESR2 (0.43) | ESR2CYP2C9OPRL1ALDH1A1LMNA | |
| SCHEMBL8429985 | 0.82 | ESR2 (0.41) | ESR2DGAT1CYP2C9ALDH1A1LMNA | |
| SCHEMBL8767263 | 0.82 | ESR2 (0.43) | ESR2CYP2C9OPRL1ALDH1A1LMNA | |
| SCHEMBL12371011 | 0.80 | NOTUM (0.34) | CYP2C9MAPTNOTUMTNKSTNKS2 | |
| SCHEMBL9326566 | 0.79 | CYP2C9 (0.49) | ESR2DGAT1CYP2C9ALDH1A1LMNA | |
| SCHEMBL9326571 | 0.79 | CYP2C9 (0.49) | ESR2DGAT1CYP2C9ALDH1A1LMNA | |
| SCHEMBL9326562 | 0.79 | CYP2C9 (0.49) | ESR2DGAT1CYP2C9ALDH1A1LMNA | |
| SCHEMBL9764302 | 0.78 | CYP2C9 (0.42) | ESR2CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL9764310 | 0.78 | CYP2C9 (0.42) | ESR2CYP2C9ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | OGDH, OXGR1, OXER1 | ESR2 852/4885DGAT1 2078/4885CYP2C9 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.